Serplulimab Clinical Trials
26 recruitingDrug
Phase 224Phase 11Phase 31Not Applicable1
Showing 1–20 of 26 trials
Recruiting
Phase 2
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials36 enrolled1 locationNCT05957510
Recruiting
Phase 2
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Colorectal CarcinomaOligometastasespMMR+2 more
First Affiliated Hospital of Zhejiang University51 enrolled1 locationNCT06850103
Recruiting
Phase 2
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Locally Advanced Rectal CarcinomapMMRMSS+1 more
Zhejiang University50 enrolled1 locationNCT05731726
Recruiting
Phase 2
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric CancerEsophagogastric Junction Adenocarcinoma
Zekuan Xu30 enrolled1 locationNCT06461910
Recruiting
Phase 2
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Shanghai Henlius Biotech60 enrolled1 locationNCT07269782
Recruiting
Phase 2
Serplulimab for Locally Advanced Cervical Cancer
Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital216 enrolled1 locationNCT07340489
Recruiting
Phase 2
Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Cervical Cancers
Tianjin Medical University Cancer Institute and Hospital134 enrolled1 locationNCT06727617
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
Solid Tumor Cancer
Shanghai Henlius Biotech105 enrolled3 locationsNCT06848699
Recruiting
Phase 2
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Colon Cancer
Ruijin Hospital56 enrolled1 locationNCT06368141
Recruiting
Phase 2
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Esophageal Squamous Cell Carcinoma
Fujian Medical University Union Hospital90 enrolled1 locationNCT06601309
Recruiting
Phase 2
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University138 enrolled1 locationNCT07150949
Recruiting
Phase 2
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
HR+/HER2- Breast Cancer
Henan Cancer Hospital357 enrolled1 locationNCT06860529
Recruiting
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Breast Cancer Invasive
Henan Cancer Hospital709 enrolled1 locationNCT06781281
Recruiting
Phase 2Phase 3
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University156 enrolled1 locationNCT06280495
Recruiting
Phase 2
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital37 enrolled1 locationNCT06422858
Recruiting
Phase 2
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
Advanced Colorectal CarcinomaImmunotherapy
Fudan University208 enrolled10 locationsNCT06521866
Recruiting
Not Applicable
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
Gastric Cancer
Tang-Du Hospital96 enrolled6 locationsNCT06128252
Recruiting
Phase 2
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University59 enrolled7 locationsNCT05585580
Recruiting
Phase 2
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Non-small Cell Lung CancerLocally Advanced
Shanghai Pulmonary Hospital, Shanghai, China100 enrolled1 locationNCT05766800
Recruiting
Phase 2
Serplulimab Combined With CCRT for LS-SCLC.
Small Cell Lung Cancer
Peking Union Medical College Hospital96 enrolled1 locationNCT06295926